Author/Authors :
Schwartz MD، نويسنده , , PhD، نويسنده , , Gregory G and Oliver MD، نويسنده , , FRCP، نويسنده , , Michael F and Ezekowitz MD، نويسنده , , PhD، نويسنده , , Michael D and Ganz MD، نويسنده , , Peter and Waters MD، نويسنده , , David and Kane MD، نويسنده , , PhD، نويسنده , , John P and Texter MS، نويسنده , , Michele and Pressler MD، نويسنده , , Milton L and Black MD، نويسنده , , Donald and Chaitman MD، نويسنده , , Bernard R a، نويسنده ,
Abstract :
The goal of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study is to determine whether early, rapid, and profound cholesterol lowering therapy with atorvastatin can reduce early recurrent ischemic events in patients with unstable angina or non–Q-wave acute myocardial infarction. Within 1 to 4 days of hospitalization for one of these conditions, 2,100 patients will be randomly assigned to receive atorvastatin, 80 mg/day, or placebo in a double-blind design. Both groups receive dietary counseling. Over a 16-week follow-up period, the primary outcome measure is the time to occurrence of an ischemic event, defined as death, nonfatal acute myocardial infarction, cardiac arrest with resuscitation, or recurrent symptomatic myocardial ischemia requiring emergency rehospitalization. Secondary outcome measures are the time to occurrence and incidence of each of the primary outcome components, as well as nonfatal stroke, worsening angina, congestive heart failure requiring hospitalization, and need for coronary revascularization not anticipated before randomization. The sample size of 1,050 patients in each group is expected to provide 95% power to detect a 30% reduction in the primary outcome measure with a 5% level of significance. The results of the MIRACL study will determine the utility of profound cholesterol lowering as an early intervention in acute coronary syndromes.
